Genmab A/S to Present at Upcoming Healthcare Conference
Genmab A/S (Nasdaq: GMAB) has announced that its Chief Executive Officer, Jan van de Winkel, Ph.D., along with Chief Financial Officer Anthony Pagano, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. This event is scheduled for the early evening and will feature opening remarks followed by a Q&A session, providing an opportunity for meaningful interaction with the audience.
Event Details
The fireside chat is set for September, and attendees can look forward to an in-depth discussion about Genmab's strategic initiatives and innovative pipeline. A webcast of the entire event will be available on Genmab’s official website, allowing a broader audience to engage with the conversation.
Focus on Innovation
Genmab is leading the way in biotechnology, concentrating on the creation of novel antibody therapeutics aimed at enhancing patient outcomes. The company’s dedication to innovation has led to the development of a pipeline that features bispecific T-cell engagers and antibody-drug conjugates. These advanced therapies are specifically designed to address various serious diseases, particularly cancers.
Company Vision and Goals
Founded in 1999, Genmab envisions a future where it can significantly improve patient care through its groundbreaking therapies, known as KYSO® antibody medicines. By focusing on enhancing the lives of individuals with severe diseases, Genmab not only strives for effective drug development but also aims to make a meaningful impact on patient populations worldwide.
About Genmab A/S
Based in Copenhagen, Denmark, Genmab has built a collaborative and passionate team over the past 25 years. Its workforce is dedicated to pushing the boundaries of science by utilizing advanced technology platforms and data sciences to develop pioneering therapeutics. This ambitious strategy has resulted in a proprietary pipeline that holds great promise for future therapies.
Global Presence and Collaboration
Genmab operates on a global scale, with a strong presence in North America, Europe, and the Asia Pacific region. The company’s commitment to collaboration is highlighted by its partnerships with several leading pharmaceutical organizations, which enhances its ability to accelerate drug development and maximize therapeutic impact.
Contact Information
For additional inquiries regarding Genmab’s participation and innovations, interested individuals can contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
1. What will Genmab discuss at the conference?
Genmab’s leadership is expected to discuss strategic initiatives and insights into their innovative pipeline during the fireside chat.
2. How can I access the conference?
The presentation will be available via webcast on Genmab’s official website, allowing for global participation.
3. What is Genmab’s core focus?
Genmab primarily focuses on the development of innovative antibody therapeutics to treat severe diseases, especially cancers.
4. Where is Genmab headquartered?
Genmab is headquartered in Copenhagen, Denmark, and has a strong international presence.
5. Who are the key speakers at Genmab's conference presentation?
Jan van de Winkel, Ph.D., Chief Executive Officer, and Anthony Pagano, Chief Financial Officer, will represent Genmab.
